following a full submission:
abaloparatide (Eladynos®) is accepted for restricted use within NHSScotland.
Indication under review: treatment of osteoporosis in postmenopausal women at increased risk of fracture.
SMC restriction: postmenopausal people with osteoporosis at very high risk of fracture, assessed using a validated fracture risk assessment tool.
In a randomised double-blind phase III study, abaloparatide was associated with a statistically significant reduction in the incidence of new vertebral fractures versus placebo.
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
Medicine details
- Medicine name:
- abaloparatide (Eladynos)
- SMC ID:
- SMC2764
- Indication:
Treatment of osteoporosis in postmenopausal women at increased risk of fracture.
- Pharmaceutical company
- Theramex UK LTD
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 07 July 2025